A Phase 2 interventional study of Axitinib [AG-013736] in Melanoma and Skin Neoplasms, sponsored by Pfizer. Completed at 12 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Melanoma by Pfizer — 1 open to participants now, 4 under way, 1 of them phase 3. Melanoma · Pfizer.
Among the 52 studies in Melanoma by Pfizer, this one is the 33rd largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2004, is one of 13 in phase 2, and was the 4th registered.
3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.
Browse Melanoma studies →1 of the 52 studies in Melanoma by Pfizer is open now, in 6 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, France, Netherlands and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 19 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 40 across 2,651 interventional studies indexed under Melanoma.
Median enrollment 77 across the 48 interventional studies, 496 across the 2 observational. Of the 47 that completed or were terminated, 23 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
2 of the studies in Melanoma by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Melanoma by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2 study being conducted at multiple centers in the United States and France. Patients having melanoma that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease (prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease). The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Axitinib [AG-013736]
VEGFR \[vascular endothelial growth factor Receptor\] and PDGFR \[Platelet-Derived Growth Factor Receptor\] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 147 weeks
Progression-free Survival (PFS)
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
Time frame: Baseline until the date of first documented progression or death due to any cause, assessed every 8 weeks up to 147 weeks
Duration of Response (DR)
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 147 weeks
Overall Survival (OS)
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
Time frame: Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant
Population Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations
Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.
Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 147 weeks
Plasma Concentrations of Soluble Proteins
Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
Time frame: Day 1 (pre-dose) and then every 8 weeks up to 147 weeks
| Milestone | Axitinib |
|---|---|
| Started | 32 |
| Completed | 0 |
| Not completed | 32 |
| Withdrew: Lack of efficacy | 23 |
| Withdrew: Death | 5 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal due to disease progression | 1 |
Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed responses are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Percentage of participants | Axitinib |
|---|---|
| Percentage of Participants With Objective Response (OR) | 18.8 (7.2 to 36.4) |
Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as first event date minus the date of first dose of study medication plus 1. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").
| Days | Axitinib |
|---|---|
| Progression-free Survival (PFS) | 117.5 (69.0 to 204.0) |
Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| Days | Axitinib |
|---|---|
| Duration of Response (DR) | 179.0 (151.0 to 516.0) |
Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.
| Days | Axitinib |
|---|---|
| Overall Survival (OS) | 200.5 (157.0 to 274.0) |
Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.
No measurements were reported for this outcome.
Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.
No measurements were reported for this outcome.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib | — | 18/32 (56.3%) | 32/32 (100%) |
| Event | Axitinib |
|---|---|
| General physical health deteriorationGeneral disorders | 2/32 |
| DehydrationMetabolism and nutrition disorders | 2/32 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/32 |
| Atrial fibrillationCardiac disorders | 1/32 |
| Atrial tachycardiaCardiac disorders | 1/32 |
| Cardiac arrestCardiac disorders | 1/32 |
| Abdominal pain, not otherwise specified (NOS)Gastrointestinal disorders | 1/32 |
| Intestinal perforation NOSGastrointestinal disorders | 1/32 |
| Disease progression NOSGeneral disorders | 1/32 |
| FatigueGeneral disorders | 1/32 |
| Event | Axitinib |
|---|---|
| FatigueGeneral disorders | 20/32 |
| HypertensionVascular disorders | 14/32 |
| NauseaGastrointestinal disorders | 13/32 |
| DysphoniaRespiratory, thoracic and mediastinal disorders | 12/32 |
| DiarrhoeaGastrointestinal disorders | 11/32 |
| Decreased appetiteMetabolism and nutrition disorders | 11/32 |
| AstheniaGeneral disorders | 10/32 |
| Weight decreasedInvestigations | 8/32 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/32 |
| InsomniaPsychiatric disorders | 8/32 |
| Age Continuous(Years) | Axitinib |
|---|---|
| Mean | 62.40 ± 15.56 |
| Sex: Female, Male(Participants) | Axitinib |
|---|---|
| Female | 15 |
| Male | 17 |
The record gives a start of Dec 2004, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 3 years 11 months after primary completion. A results delay was requested in Mar 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib